Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Zevona XL 30mg prolonged release tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Isosorbide mononitrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for The name of your medicine is Zevona XL 30 mg prolonged-release tablets, referred to as Zevona XL tablets throughout this leaflet. Zevona XL tablets contain the active ingredient isosorbide mononitrate, which belongs to a group of medicines called nitrates.
- It is used to prevent chest pain (angina)
- It works by making the blood vessels relax and widen. This makes it easier for the heart to pump blood around the body. The tablets are made so that they release the medicine slowly over a number of hours.
What you need to know before you take it
e Zevona XL tablets Do not take Zevona XL tablets
- if you are allergic to isosorbide mononitrate or any of the other ingredients of this medicine (listed in section 6)
- if you have ever had a stroke
- if you have very low blood pressure
- if you have severe anaemia
- if you have a heart problem called "cardiomyopathy" or "pericarditis" or you have narrow heart valves
- if you are taking sildenafil or similar medicines called Phosphodiesterase Type 5 Inhibitors (used for male impotence). See section "Other medicines and Zevona XL tablets".
- if you are also taking riociguat. See section "Other medicines and Zenova XL tablets". Do not take Zevona XL tablets if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Zevona XL tablets. Warnings and precautions Talk to your doctor or pharmacist before taking Zevona XL tablets if:
- You have ever had any serious damage to your heart, such as a heart attack or operation. If any of the above apply to you, or you are not sure, talk to your doctor or pharmacist before taking Zevona XL tablets. Other medicines and Zevona XL tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Zevona XL tablets can affect the way some medicines work
and some medicines can have an effect on Zevona XL tablets. Do not take Zevona XL tablets if you are taking the following medicines:
- Sildenafil or similar medicines called Phosphodiesterase Type 5 Inhibitors, (used for male impotence).
- Riociguat, as this can cause hypotension (abnormally low blood pressure). Do not take Zevona XL tablets if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Zevona XL tablets. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines You may feel dizzy after taking Zevona XL tablets. If this happens, do not drive or use any tools or machines. Zevona XL tablets contain lactose Zevona XL tablets contain a type of sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
How to take it
Zevona XL tablets Always take this medicine exactly as your doctor, or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Taking this medicine
- Swallow the tablets whole
- Take the tablets with half a glass of water
- Do not crush or chew the tablets How much to take
- The recommended dose is 60 mg (two tablets) or 120mg (4 tablets) a day
- Take the medicine in the morning
- Your doctor may ask you to start on a low dose so that you are less likley to have a reaction to starting Zevona XL tablets. You must not take Zevona XL tablets for a sudden attack of angina. If you have a sudden attack, take a glyceryl trinitrate tablet (follow the instructions given on the label). Very occasionally, some users may see the remnants of the tablet in their bowel motions. This is quite normal and does not mean that the medicine has not been released. Use in children Do not give these tablets to children. If you take more Zevona XL tablets than you should If you take more Zevona XL tablets than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you to the tablets can be identified. If you forget to take Zevona XL tablets
- If you forget a dose take it as soon as you remember it. However if it is nearly time for the next dose, skip the missed dose.
- Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, this medicine may cause side effects, although not everybody gets them. The following side effects may happen with this medicine:
- Headaches.
- Feeling sick (nausea).
- Feeling dizzy. The above problems usually disappear with time.
Other possible side effects Common (may affect up to 1 in 10 people)
- low blood pressure. This may make you feel faint or dizzy
- faster heartbeat
- headache
- feeling dizzy
- feeling sick (nausea) Uncommon (may affect up to 1 in 100 people)
- being sick (vomiting)
- diarrhoea Rare (may affect up to 1 in 1,000 people)
- fainting
- rash
- itchy skin Very rare (may affect up to 1 in 10,000 people)
- pain in muscles Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
Possible side effects
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
How to store it
Zevona XL tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Contents of the pack and other information
What Zevona XL tablets contain
- The active substance is isosorbide mononitrate. Each tablet contains 30 mg of isosorbide mononitrate.
- The other ingredients are: hypromellose, lactose monohydrate, pregelatinised starch, magnesium stearate, silica colloidal anhydrous. What Zevona XL tablets looks like and contents of the pack Zevona XL tablets are white to off-white, oval prolonged-release tablets. Zevona XL tablets are packaged blister packs containing 28 tablets. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Zentiva Pharma UK Limited 12 New Fetter Lane London EC4A 1JP United Kingdom Manufacturer: Astrea Fontaine SAS Rue de Prés Potets 21121 Fontaine les Dijon France This leaflet was last revised in June 2026 Other sources of information
For information on large print, Braille or audio CD call emc accessibility on 0800 198 5000
1065049597
Frequently asked questions about Zevona XL 30mg prolonged release tablets
How do I take Zevona XL 30mg prolonged release tablets?
Zevona XL 30mg prolonged release tablets comes as tablet containing 30mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Zevona XL 30mg prolonged release tablets?
The active substance in Zevona XL 30mg prolonged release tablets is isosorbide mononitrate.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Zevona XL 30mg prolonged release tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Zevona XL 30mg prolonged release tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: isosorbide mononitrate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Prophylactic treatment of angina pectoris
4.2. Posology and method of administration
Posology
Adults
Usual dose is 60mg (two tablets) taken once daily in the morning. The dose may be increased to 120 mg (four tablets) daily, to be taken once daily in the morning. The dose can be titrated to minimise the possibility of headache, by initiating treatment with 30 mg (one tablet) for the first 2-4 days.
Paediatric population
The safety and efficacy of Zevona XL 30 mg prolonged-release tablets in children have not yet been established.
Elderly
No evidence of a need for routine dosage adjustment for elderly patients has been found, but special care may be needed in those with increased susceptibility to hypotension or marked hepatic or renal insufficiency.
The core of the tablet is insoluble in the digestive juices but disintegrates into small particles when all active substance has been released. Very occasionally the matrix may pass through the gastrointestinal tract without disintegrating and be found visible in the stool, but all active substance has been released.
Method of administration
Zevona XL 30 mg prolonged-release tablets must not be chewed or crushed. They should be swallowed whole with half a glass of water.
4.3. Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Constrictive cardiomyopathy and pericarditis, aortic stenosis, cardiac tamponade, mitral stenosis and severe anaemia.
- Patients treated with Zevona XL 30 mg prolonged-release tablets must not be given Phosphodiesterase Type-5 Inhibitors (e.g. sildenafil)
- Severe cerebrovascular insufficiency or hypotension are relative contraindications to the use of Zevona XL 30 mg prolonged-release tablets.
- Co-administration with riociguat (see section 4.5).
4.4. Special warnings and precautions for use
Zevona XL 30 mg prolonged-release tablets is not indicated for relief of acute angina attacks; in the event of an acute attack, sublingual or buccal glyceryl trinitrate tablets should be used.
Excipients
This medicinal product contains lactose. Patients with any of the following rare hereditary conditions: galactose intolerance, total lactase deficiency or glucose-galactose malabsorption; should not take this medicine.
4.5. Interaction with other medicinal products and other forms of interaction
Concomitant administration of Zevona XL 30 mg prolonged-release tablets and Phosphodiesterase Type-5 Inhibitors can potentiate the vasodilatory effect of Zevona XL mg prolonged-release tablets with the potential result of serious side effects such as syncope or myocardial infarction. Therefore, Zevona XL 30 mg prolonged-release tablets and Phosphodiesterase Type-5 Inhibitors (e.g. sildenafil) must not be given concomitantly.
The use of isosorbide mononitrate with riociguat, a stimulator of soluble guanylate cyclase, is contra-indicated (see section 4.3), since concomitant use can cause hypotension.
4.6. Fertility, pregnancy and lactation
The safety and efficacy of Zevona XL 30 mg prolonged-release tablets during pregnancy have not been established.
4.7. Effects on ability to drive and use machines
Patients may develop dizziness when first using Zevona XL 30 mg prolonged-release tablets. Patients should be advised to determine how they react to Zevona XL 30 mg prolonged-release tablets before they drive or operate machinery.
4.8. Undesirable effects
Most of the undesirable effects are pharmacodynamically mediated and dose-dependent.
Headache may occur when the treatment is initiated, but usually disappears after 1-2 weeks of treatment. The dose can be titrated to minimise the possibility of headache, by initiating treatment with 30 mg. Hypotension, with symptoms such as dizziness and nausea with syncope in isolated cases, has occasionally been reported. These symptoms generally disappear during continued treatment.
The following definitions of frequencies are used: Very common (≥ 1/10), Common (≥ 1/100 to <1/10), Uncommon (≥ 1/1,000 to <1/100), Rare (≥ 1/10,000 to <1/1,000) and Very rare (<1/10,000), Rate not known (cannot be estimated from available data).
Adverse drug reactions by frequency and system organ class (SOC)
System organ class
Frequency
Reaction
Nervous system disorders
Common
Headache, dizziness
Rare
Fainting
Cardiac and vascular disorders
Common
Hypotension, tachycardia
Gastrointestinal tract disorders
Common
Nausea
Uncommon
Vomiting, diarrhoea
Skin and subcutaneous tissue disorders
Rare
Rash, pruritus
Musculoskeletal and connective tissue disorders
Very rare
Myalgia
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Symptoms
Pulsing headache. More serious symptoms include excitation, flushing, cold perspiration, nausea, vomiting, vertigo, syncope, tachycardia and a fall in blood pressure.
Management
Induction of emesis, activated charcoal. In the case of pronounced hypotension the patient should first be placed in the supine position with the legs raised. If necessary fluids should be administered intravenously.
💬 Ask about this leaflet
Ask anything about Zevona XL 30mg prolonged release tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
Medicines containing Isosorbide mononitrate
- Carmil XL 60 mg Tablets
- Chemydur 60XL Tablets
- Elantan LA 25 mg prolonged release capsules
- Elantan LA 50 mg prolonged release capsules
- Eumon 40 XL Modified Release Tablets (Isosorbide Mononitrate)
- Imdur Tablets 60mg
- ISMO 10, 10 mg, tablets
- ISMO 20, 20 mg, tablets
- ISMO Retard, 40 mg, prolonged-release tablets
- Isodur 25XL Capsules
- Isodur 50XL Capsules
- Isosorbide Mononitrate 10 mg Tablet
- Isosorbide Mononitrate 20 mg Tablet
- Isosorbide Mononitrate 40 mg Tablet